C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience
Glasgow, Scotland, and Sheffield, UK, 12th December 2016 – Mironid Ltd, a leader in cell signalling-directed drug development, and the University of Sheffield, announced today
Mironid is delighted to announce that Prof Albert Ong DM MA FRCP, Professor of Renal Medicine, Department of Infection Immunity & Cardiovascular Disease, University of
Louisville, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim
Brighton, UK, November 10, 2016: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of
Originally published October 31, 2016 in Invest Edinburgh A new biotech company called Nodthera has been launched in Edinburgh to develop potential treatments for a
Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma
Brighton, UK, October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment
Edinburgh, Scotland, October 7, 2016 – At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company
LOUISVILLE, Ky., Aug. 8, 2016 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the expansion of its executive team with the addition of Dr.